Skip to main content

Table 2 Change of primary outcome measures in risperidone long acting injection and paliperidone palmitate groups

From: Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial

 

RLAI group

PP group

Difference in change between groups

 

Baseline

Change

Baseline

Change

p

Partial eta-squared

95%CI

 

Mean

SD

Mean

SD

Mean

SD

Mean

SD

   

BACS

           

 Verbal learning

6

1.04

.23

1.59

−1.34

.94

.06

1.22

.597

.017

−1.88 to 1.10

 Working memory

−2.12

1.15

.12

.77

−1.10

.91

.26

.62

.412

.040

−1.09 to .470

 Motor function

−2.65

.75

.28

.99

−2.74

1.09

.80

1.31

.374

.047

−1.80 to .71

 Verbal fluency

−1.60

.83

.12

.50

−1.35

.97

.48

.60

.174

.106

−.93 to .18

 Attention and processing speed

−2.65

1.37

.32

.36

−1.69

1.33

.62

.36

.039*

.228

−.79 to -.02

 Executive function

−2.03

2.80

.63

2.69

−.44

1.09

−.13

.99

.171

.107

−1.76 to .34

 Composite score

−2.22

.95

.29

.49

−1.44

.58

.35

.52

.290

.066

−.80 to .25

  1. *p < .05